A Glimpse into the Future: DNA Methylation Market Projections By 2023 to 2033
The global DNA methylation industry is anticipated to reach a market size of US$ 1437.5 Million in 2023 and US$ 5815.49 Million by 2033, showing a CAGR of 15% during that time. The biggest factor expected to contribute to the DNA Methylation Industry’s expected rise is the rising incidence of cancer worldwide. From 2016 to 2021, the market for DNA methylation experienced a CAGR of 11%.
The DNA Methylation Industry has gained significant attention in recent years due to its potential applications in various fields, including medical research, diagnostics, and personalized medicine. DNA methylation is an epigenetic modification that plays a crucial role in gene regulation, and aberrant DNA methylation patterns have been linked to numerous diseases, such as cancer, neurological disorders, and autoimmune conditions. As a result, the demand for DNA methylation analysis tools and services has been steadily increasing, driving the growth of the DNA Methylation Industry.
Request A Sample Copy Of This Research Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-15893
One of the primary factors contributing to the expansion of the DNA Methylation Industry is the growing understanding of the role of DNA methylation in disease development and progression. Researchers and clinicians have recognized the significance of DNA methylation as a potential biomarker for early detection, prognosis, and treatment response prediction. By analyzing the DNA methylation patterns, scientists can gain insights into the molecular mechanisms underlying diseases and develop targeted therapies accordingly.
Moreover, technological advancements have propelled the DNA Methylation Industry forward. High-throughput sequencing technologies, such as next-generation sequencing (NGS), have revolutionized DNA methylation analysis by enabling the simultaneous investigation of the entire genome. These advanced techniques provide researchers with unprecedented resolution and accuracy, allowing them to identify specific DNA methylation changes associated with different diseases. The development of cost-effective and user-friendly DNA methylation analysis platforms has also contributed to the widespread adoption of DNA methylation analysis in both research and clinical settings.
Key Takeaways from the Market Study:
- By technology, sequencing is expected to possess 35% market share for DNA Methylation Industry in 2023.
- By product, consumables are expected to possess 35% market share for DNA Methylation Industry in 2023.
- By application, clinical research is expected to possess 40% market share for DNA Methylation Industry in 2023.
- By application, diagnostic segment is anticipated to witness the fastest growth in the coming years with a CAGR of 16%.
- By end use, pharmaceutical and biotechnology end-use segment are expected to possess 42% market share for DNA methylation in 2023.
- North America is expected to possess 40% market share for DNA Methylation Industry in 2023.
- Asia Pacific is expected to possess 38% market share for DNA Methylation Industry in 2023.
“Expenditure on research and development along with government funding is expected to accelerate the growth of DNA Methylation Industry.” comments a Future Market Insights analyst.
Competitive Landscape:
- Some prominent players in the global DNA Methylation Industry include New England Biolabs
- Sysmex Corporation
- Abcam plc.
- F. Hoffmann-La Roche Ltd.
- Diagenode Diagnostics S.A.
- Thermo-Fisher Scientific Inc.
- Agilent Technologies Inc.
- BioRad Laboratories Inc.
- Exact Sciences Corporation
- QIAGEN N.V.
- Active Motif, Inc.
- Illumina Inc.
- EpiGentek Group Inc.
In May 2022, Oxford Nanopore announced integrating Remora, a technique that offers accurate and real-time epigenetic insights with nanopore sequencing software. This would further offer simple access to accurate whole genome methylation detection.
In June 2020, Base Genomics announced of advancing and developing its DNA methylation technology. the aim is to sequence a large amount of epigenetic data from a blood test which could revolutionize the preventative medicine arena.
Key Segments Profiled in the DNA Methylation Industry Survey:
Technology:
- Polymerase Chain Reaction (PCR)
- Microarray
- Sequencing
- Others
Product:
- Consumables
- Kits & Reagents
- Enzymes
- Instruments & Software
Application:
- Gene Therapy
- Clinical Research
- Diagnostics
- Others
End-use:
- Hospital & Diagnostic Laboratories
- Pharmaceutical & Biotechnology Companies
- Research & Academia
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
